复杂的皮肤冠状动脉干预和心脏性冲击患者的抗血栓治疗
Jose Ignacio Larrubia Valle1, Cristóbal A Urbano-Carrillo1, Francesco Costa2
1Unidad de Gestión Clínica de Cardiología, Hospital Regional Universitario de Malaga, Malaga 29010, Spain.
Interventional cardiology clinics
|September 8, 2024
概括
管理复杂的PCI和心脏性休克的抗血栓治疗需要仔细平衡疗效和风险. 不分离的肝素是标准的,在特定情况下,可选择比瓦利鲁丁和坎格雷勒作为替代品.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在接受皮肤冠状动脉干预 (PCI) 或心脏性休克 (CS) 的高风险患者中管理抗血栓治疗具有重大挑战.
- 优化抗血栓策略对于改善这些复杂患者群体的治疗结果至关重要.
研究的目的:
- 审查在高风险患者PCI期间和之后抗血栓治疗的关键作用.
- 讨论优化疗效的策略,同时尽量减少与抗血栓剂相关的出血风险.
主要方法:
- 文献综述侧重于复杂的PCI和心脏性休克中的抗血栓治疗.
- 对当前关于抗凝血剂和抗血小板治疗的指导方针和证据的分析.
主要成果:
- 未分离的氨酸是复杂的PCI和CS的主要抗凝剂.
- 比瓦利鲁丁作为一种潜在的更安全的替代抗凝剂.
- 康格洛尔提供可靠的抗血小板作用,特别是当口服药物的吸收延迟或不确定时.
结论:
- 对于接受复杂PCI或CS的患者来说,仔细选择和管理抗血栓治疗是必不可少的.
- 像比瓦利鲁丁和坎格雷罗尔这样的替代药物为减轻风险和优化特定临床场景中的治疗提供了有价值的选择.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
652
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
652
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
499
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
499
Blood Pressure Imbalances and Circulatory Shock
762
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
762
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
147
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
147
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
160
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
160


